June Off to a Poor ...
Health Care: Drugs
Amgen Inc (AMGN: NASDAQ)
$67.75 -1.77 | -2.55%
06/01/12 - 04:00 PM ET
Company Balance Sheet
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 6.95B | 3.29B | 2.88B | 1.77B |
| Receivables | 2.90B | 2.34B | 2.11B | 2.07B |
| Inventories | 2.48B | 2.02B | 2.22B | 2.08B |
| Other Current Assets | 1.57B | 1.35B | 1.16B | 1.52B |
| Total Current Assets | 27.59B | 23.13B | 18.93B | 15.22B |
| Property, Plant & Equipment, Gross | 11.23B | 10.69B | 10.38B | 10.00B |
| Accumulated Depreciation & Depletion | 5.81B | 5.17B | 4.64B | 4.12B |
| Property, Plant & Equipment, Net | 5.42B | 5.52B | 5.74B | 5.88B |
| Intangibles | 2.58B | 2.23B | 2.57B | 2.99B |
| Other Non-Current Assets | 1.52B | 1.27B | 1.06B | 1.02B |
| Total Non-Current Assets | 21.28B | 20.36B | 20.70B | 21.22B |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 48.87B | 43.49B | 39.63B | 36.44B |
| Accounts Payable | 642.00M | 716.00M | 574.00M | 504.00M |
| Short Term Debt | 0.00 | 0.00 | 0.00 | 1.00B |
| Other Current Liabilities | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Liabilities | 5.75B | 6.57B | 3.87B | 4.89B |
| Long Term Debt | 21.34B | 10.87B | 10.60B | 9.18B |
| Deferred Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Liabilities | 2.74B | 2.10B | 2.49B | 2.00B |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 24.09B | 12.97B | 13.09B | 11.17B |
| Total Liabilities | 29.84B | 19.54B | 16.96B | 16.06B |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | 19.03B | 23.94B | 22.67B | 20.39B |
| Common Par | 27.78B | 27.30B | 26.94B | 25.53B |
| Additional Paid In Capital | 0.00 | 0.00 | 0.00 | 0.00 |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 25.00M |
| Retained Earnings | -8.92B | -3.51B | -4.32B | -5.26B |
| Treasury Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Equity Adjustments | 171.00M | 153.00M | 45.00M | 92.00M |
| Total Capitalization | 40.37B | 34.82B | 33.27B | 29.56B |
| Total Equity | 19.03B | 23.94B | 22.67B | 20.39B |
| Total Liabilities & Stock Equity | 48.87B | 43.49B | 39.63B | 36.44B |
| Total Common Shares Outstanding | 795.60M | 932.00M | 995.00M | 1.05B |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic Weighted Shares Outstanding | 905.00M | 960.00M | 1.02B | 1.07B |
| Diluted Weighted Shares Outstanding | 912.00M | 965.00M | 1.02B | 1.08B |
| Number of Employees | 17500 | 17100 | 17000 | 17400 |
| Number of Part-Time Employees | 300 | 300 | 200 | 100 |
Portfolios with AMGN
- Portfolio NameUser Type
- UserLong Term Stock Picks by Co...
- Contributor5 Low Volatility Low PEG St...
- UserJimboPhi
- UserCorporate Communication cla...
- UserKAREL VON ZOETE
- UserMACHINE RECOMMENDATIONS
- UserMARIA DEL HUERTO
- ContributorHighest-Yielding Drug Stocks
- Contributor10 Health Care Stocks to Watch
- ContributorMost-Searched Stocks for th...
Latest AMGN Headlines from TheStreet
- Symmetry Projections
05.21.12 | 08:05 am - Amgen Inc (AMGN): Today's Featured Drugs Loser 05.18.12 | 05:05 pm
- 5 Cheap, Low-Risk Stocks to Buy 05.18.12 | 07:05 am
- Amgen Stock To Go Ex-dividend Monday (AMGN) 05.11.12 | 08:05 am
- Ex-Dividend Stocks: Target, ConEd 05.11.12 | 07:05 am
- Amgen Inc (AMGN): Today's Featured Drugs Winner 05.10.12 | 05:05 pm
- Amgen Inc (AMGN): Today's Featured Drugs Winner 05.02.12 | 04:05 pm
- Amgen Reaches New 52-Week High (AMGN) 04.25.12 | 01:04 pm
- Amgen Goes to Turkey, Loses Biotech Cred 04.25.12 | 09:04 am
- Amgen's CEO Discusses Q1 2012 Results - Earnings Call Transcript 04.24.12 | 10:04 pm
Press Releases for AMGN
- Amgen Announces Voting Results Of Annual Meeting Of Stockholders - PR Newswire 05.23.12 | 05:05 pm
- Amgen's BiTE® Antibody Blinatumomab (AMG 103) Achieved High Rate Of Complete Response In Adult Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia - PR Newswire 05.16.12 | 06:05 pm
- Analysis Of Rilotumumab (AMG 102) Data Identifies A Potential Predictive Biomarker For Patients With Gastric Or Gastroesophageal Cancer - PR Newswire 05.16.12 | 06:05 pm
- Amgen To Present At The Baird Growth Stock Conference - PR Newswire 05.04.12 | 04:05 pm
- Amgen To Present At The Deutsche Bank 37th Annual Healthcare Conference - PR Newswire 05.03.12 | 06:05 pm
- Amgen Receives Complete Response Letter From FDA For XGEVA® SBLA For Prevention Of Bone Metastases - PR Newswire 04.26.12 | 10:04 pm
- Amgen To Acquire Mustafa Nevzat, A Leading Privately Held Turkish Pharmaceutical Company - PR Newswire 04.25.12 | 02:04 am
- A Tribute To George Rathmann, Amgen's Founding CEO (1927-2012) - PR Newswire 04.23.12 | 10:04 pm
- Amgen To Acquire Privately Held KAI Pharmaceuticals - PR Newswire 04.10.12 | 08:04 am
- UCB And Amgen Initiate Sclerostin Antibody Phase 3 Program In Patients With Postmenopausal Osteoporosis - PR Newswire 04.04.12 | 01:04 am
Partner Headlines for AMGN
- Health Care SPDR In Focus Ahead Of Obamacare Decision - Benzinga 05.22.12 | 12:05 pm
- The Definitive Biotech ETF Guide (IBB, XBI, FBT) - Benzinga 05.21.12 | 01:05 pm
- Medgenics Moving In Record Time - Seeking Alpha 05.21.12 | 09:05 am
- Amgen Beats but Maintains Outlook - Analyst Blog - Zacks 04.25.12 | 10:04 am
- Top Undervalued High Conviction Outperforming Picks From Eaton Vance's $47 Billion Q1 Filng - Seeking Alpha 04.20.12 | 10:04 pm
- Earnings Preview: Abbott Labs - Analyst Blog - Zacks 04.17.12 | 10:04 am
- The Zacks Analyst Blog Highlights: The Goldman Sachs Group, Lloyd's, Bank of America, JPMorgan Chase and Amgen - Press Releases - Zacks 04.12.12 | 09:04 am
- Market Roundup - Benzinga 04.10.12 | 01:04 pm
- Time To Take Another Look At The Biotechnology Sector - Seeking Alpha 04.09.12 | 09:04 am
- Amgen, Abbott, Teva All Incredibly Undervalued Stocks - Seeking Alpha 04.06.12 | 07:04 am
